Search results (1345)
« Back to PublicationsMolecular profiling in MPN: who should have it and why?
Chee A. and Mead AJ., (2024), Hematology Am Soc Hematol Educ Program, 2024, 524 - 534
Treatment of the blood cancer polycythemia vera with ruxolitinib in the MAJIC-PV study: a plain language summary.
Harrison CN. et al, (2024), Future Oncol, 20, 3365 - 3376
INCA033989: the first shot on goal for MPNs?
Benlabiod C. and Psaila B., (2024), Blood, 144, 2278 - 2279
When, which and how to switch: Navigating JAK inhibitors in myelofibrosis
O'Sullivan J. et al, (2024), British Journal of Haematology
Redefining PD1 as a guardian of stem-like T cells.
Jackson M. and Parkes EE., (2024), Nat Rev Immunol
Validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries: a retrospective, comparative analysis.
Jackson A. et al, (2024), Lancet Oncol, 25, 1476 - 1486
A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis.
Li R. et al, (2024), Sci Transl Med, 16
Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer.
Javed SR. et al, (2024), Br J Cancer
Genome-wide association studies of Down syndrome associated congenital heart defects
Feldman ER. et al, (2024)